In this issue of JAMA Internal Medicine, Feldman and colleagues1 report that Medicare spending on insulin for patients with diabetes was an estimated $7.8 billion, which is $4.4 billion more than the Centers for Medicare & Medicaid Services might have spent by using the prices negotiated by the US Department of Veterans Affairs and their formulary restrictions. Even if the $4.4 billion figure overestimates the potential savings, the potential for lower prices would substantially increase many patients’ access to life-saving insulin products.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Steinbrook R. Decreasing Medicare Spending on Prescription Drugs. JAMA Intern Med. 2020;180(4):601. doi:10.1001/jamainternmed.2019.7064
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: